

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/583,280 – Conf. # 2639
				Filing Date	June 16, 2006
				First Named Inventor	Charles Sawyers
				Art Unit	1636
				Examiner Name	Nancy S. Vogel
Sheet	3	of	7	Attorney Docket Number	58086-232451

	C13	Kingsman et al., <u>Gene</u> , 7: 141 (1979).	
	C14	Tschumper et al., <u>Gene</u> , 10: 157 (1980).	
	C15	Jones, <u>Genetics</u> , 85:23 (1977).	
	C16	Feldman, B.J. & Feldman, D. The development of androgen-independent prostate cancer. <u>Nat Rev Cancer</u> 1, 34-45 (2001).	
	C17	Gelmann, E.P. Molecular biology of the androgen receptor. <u>J Clin Oncol</u> 20, 3001-15 (2002).	
	C18	Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. <u>Urology</u> 60, 132-8; discussion 138-9 (2002).	
	C19	Taplin, M.E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. <u>Cancer Res</u> 59, 2511-5 (1999).	
	C20	Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. <u>J Clin Oncol</u> 21, 2673-8 (2003).	
	C21	Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. <u>Nat Genet</u> 9, 401-6 (1995).	
	C22	Taplin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. <u>N Engl J Med</u> 332, 1393-8 (1995).	
	C23	Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. <u>Biochem Biophys Res Commun</u> 173, 534-40 (1990).	
	C24	Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. <u>J Med Chem</u> 45, 1439-46 (2002).	
	C25	Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. <u>Nat Med</u> 5, 280-5 (1999).	
	C26	Gioeli, D. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. <u>J Biol Chem</u> 277, 29304-14 (2002).	
	C27	Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. <u>Science</u> 270, 1491-4 (1995).	
	C28	Font de Mora, J. & Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. <u>Mol Cell Biol</u> 20, 5041-7 (2000).	
	C29	Tremblay, A., Tremblay, G.B., Labrie, F. & Giguere, V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. <u>Mol Cell</u> 3, 513-9 (1999).	
	C30	Gregory, C.W. et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. <u>Cancer Res</u> 61, 4315-9 (2001).	
	C31	Li, P. et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. <u>Am J Pathol</u> 161, 1467-74 (2002).	
	C32	Glass, C.K. & Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. <u>Genes Dev</u> 14, 121-41 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--